Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Argatroban

FDA-approved product (injectable, injection), marketed as Argatroban, Argatroban In 0.9% Sodium Chloride, Argatroban In Dextrose and 1 more.

Registered studies
38
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Argatroban
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Recurrent thrombophlebitis
  • Thrombocytopenia
  • Thrombotic disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Direct thrombin inhibitors
FDA pharmacologic class
Anti-coagulant; Direct Thrombin Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA48.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli52.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

38registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Argatroban in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Argatroban with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Comparative Sudy Comparing Argatroban® IV vs Desirudin SC for Suspected HIT With or Without Thrombosis Syndrome

    NCT00787332 · start 2008-09

    Registered record
    Registry ID
    NCT00787332
    Conditions
    Suspected Heparin-Induced Thrombocytopenia
    Interventions
    Desirudin or Argatroban®
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2008-09
    Completion
    2009-12
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSuspected Heparin-Induced Thrombocytopenia
    InterventionDesirudin or Argatroban®
    PhasePhase 4
    Registry statusTerminated

  • Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT)

    NCT00603824 · start 2008-01

    Registered record
    Registry ID
    NCT00603824
    Conditions
    Heparin-Induced Thrombocytopenia
    Interventions
    fondaparinux; argatroban or lepirudin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2008-01
    Completion
    2010-07
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeparin-Induced Thrombocytopenia
    Interventionfondaparinux; argatroban or lepirudin
    PhasePhase 4
    Registry statusWithdrawn

  • Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)

    NCT00508924 · start 2005-08

    Registered record
    Registry ID
    NCT00508924
    Conditions
    Coronary Artery Disease; Angina, Unstable
    Interventions
    Argatroban; Argatroban; Argatroban; Heparin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-08
    Completion
    2006-10
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease; Angina, Unstable
    InterventionArgatroban; Argatroban; Argatroban; Heparin
    PhasePhase 2
    Registry statusCompleted

  • Efficacy and Safety Study of Argatroban to Treat Heparin-Induced Thrombocytopenia

    NCT00198588 · start 2005-06

    Registered record
    Registry ID
    NCT00198588
    Conditions
    Heparin-Induced Thrombocytopenia
    Interventions
    argatroban
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-06
    Completion
    2006-09
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeparin-Induced Thrombocytopenia
    Interventionargatroban
    PhasePhase 3
    Registry statusCompleted

  • Edaravone and Argatroban Stroke Therapy Study for Acute Ischemic Stroke

    NCT00153946 · start 2004-08

    Registered record
    Registry ID
    NCT00153946
    Conditions
    Stroke
    Interventions
    Edaravone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-08
    Completion
    2008-05
    Enrolment
    814

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStroke
    InterventionEdaravone
    PhasePhase 4
    Registry statusCompleted

  • Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin

    NCT00039858 · start 2003-09

    Registered record
    Registry ID
    NCT00039858
    Conditions
    Thrombocytopenia; Thrombosis
    Interventions
    Argatroban
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-09
    Completion
    2006-03
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThrombocytopenia; Thrombosis
    InterventionArgatroban
    PhasePhase 4
    Registry statusCompleted

  • Argatroban Stroke Treatment - A Pilot Safety Study

    NCT00268762 · start 2003-02

    Registered record
    Registry ID
    NCT00268762
    Conditions
    Ischemic Stroke
    Interventions
    argatroban
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2003-02
    Completion
    2010-08
    Enrolment
    65

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIschemic Stroke
    Interventionargatroban
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Pharmacokinetics/Pharmacodynamics of Argatroban Injection in End-Stage Renal Disease Patients Undergoing Hemodialysis

    NCT00035178 · start 2002-05

    Registered record
    Registry ID
    NCT00035178
    Conditions
    Kidney Failure, Chronic; Renal Disease, End-Stage
    Interventions
    Argatroban
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-05
    Completion
    2002-11
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Failure, Chronic; Renal Disease, End-Stage
    InterventionArgatroban
    PhasePhase 4
    Registry statusCompleted